4 5-diamino-7h-pyrrolo(2 3-d)pyrimidine derivatives

ABSTRACT

THE DISCLOSURE IS DIRECTED TO DERIVATIVES OF 4,5-DIAMINO7H-PYRROLO(2,3-D)PYRIMIDINES HAVING THE STRUCTURAL FORMULA:   WHERE R1-R4 ARE AS DEFINED BELOW, AND TO THE 4,5,6-TRISUBSTITUTED PYRIMIDINES WHICH ARE INTERMEDIATES IN THEIR PREPARATION. THE COMPOUNDS HAVE CENTRAL NERVOUS SYSTEM ACTIVITY AS DEPRESSANTS THAT IS, THEY PRODUCE A CALMING EFFECT IN THE HOSE.

States Patent (315cc WW5 Patented Dec. 28, 1971 l 4 3,631,045 a and R 18 lower alkyl, p y halophenyl, lower alkylphenyl, lower alkoxyphenyl or lower alkylthio. 4,5-DIAMINO-7ll-PYRROLOD,3-d]PYRIMlDINE DERIVATIVES As used herein the terms lower alkyl and the like Don H Kim, Wayne and Arthur A sanfim Haver describe groups containing from 1 to about 4 carbon a a 9 town, Pan, assignors to American Home Products Cor- 5 atoms Duration, New York, Typical examples of the compounds of this invention N Drawing. Filed Nov. 4, 1969, Ser. No. 874,053 which are depicted by structural Formula I are: 4,5-di- Int. Cl. (107d 57/14 amino-7-methyl-2-phenyl-7g-pyrrolo[2,3 d]pyrimidine- US. Cl. 260-256.5 R 6 Claims 6-carbonitrile and -amino-4-ethylamino-2-phenyl-7g- 10 pyrrolo[2,3-d]pyrimidine-G-carboxamide.

Also within the purview of the present invention are ABSTRACT OF THE DISCLOSURE the 4,5,6-trisubstituted pyrimidines exemplified by the fol- The disclosure is directed to derivatives of 4,5-diaminolowiflg fqrmula which, is explained below, j inter 7-pyrrolo[2,3-d] pyrimidines having the structural formedlates 1n the Preparatlon 0f the compounds havlng mula: mula I:

NHR 5 I -NH qn Rl R1 T N (II) 3 where R is chloro, amino or lower alkylamino; R is Where R1 R4 are as defined below and to the 4,5,6 tri formyl, oximidomethylene and cyano; and R 1s chloro N(R )CH R where R is cyano or carboximido and substituted pyrimidines which are intermediates in then or 2 2! y preparation. The compounds have central nervous system 0 ggg i g g izggfigg z i gg fig gs g zgg? activity as depressants that is, they produce a calming 1 f h y d effect in the host Typ ca examp es 0 t e mterme late compoun s of 1s invention which are depicted by structural Formula II are: 4,6 dichloro-2-phenyl-5-pyrimidinecarboxa1dehyde; This invention relates to derivatives of 4,5-diamino-7- 4,6-diehloro-zhen l-srimidinecarboxaldehyde, oxime; methyl-7 I;I -pyrrolo[2,3-d1pyrimidines and to intermediand 4,6-dichloro-Z-phenyl-S-pyrimidinecarbonitrile.

ates for their preparation. More particularly, this inven- The new and useful compounds of this invention may tion relates to new and useful 4,5-diamino-7g-pyrrolobe prepared by the process which is hereinafter schemati- [2,3-d]pyrimidine-6- carbonitriles and 4,5-diamino-7 E cally illustrated.

(|)H ill ('31 ()1 N chlorination q condensation N/\[CH=N OH dehydration N ji a R4L\N OH formylation K C1 R4"L\N/ C1 k 01 (III) (IV) (V) (VI) aminatianl NHR 111KB IIIHR N J 'NH cyelization N/\ON amination N G1 1 l R4\N \N --R2 R' \N/ IOH2R R4N C1 l a a (1) (VIII) (VII) pyrrolo[2,3-d]pyrimidine-6-carboxamides, and to inter- Where R -R are as described above. mediates in their preparation. The invention relates to The compounds are prepared by mixing phosphorus the following intermediates: 4,6-dihalo-5-pyrimidinecaroxychloride and dimethylformamide in an ice bath and boxaldehydes; 4,6-dihalo-S-pyrimidinecarboxaldehyde, oxallowing the mixture to stand for about A to 3 hours at imes; 4,6 dihalo-S-pyrimidinecarbonitriles; 6-amino-4- a temperature of about 0 to 25 0, preferably at room halo-S-pyrimidinecarbonitriles and 6-amino-4-methylamitemperature for about one hour. A 4,6-dihydroxypyrirnino-5-pyrimidinecarbonitriles. dine is slowly added to the mixture and the resulting The compounds within the purview of the present inmixture allowed to stand for about A to 1 hour. The vention are exemplified by the 4,5-diamino7 I -pyrro10- reaction mixture then is heated for about 4 to 6 hours [2,3-d1pyrimidines having the following formula: at a temperature of about to C., preferably NHR1 about 5 hours at steam bath temperature to afford a 4,6-dihalo-5-pyrimidine carboxaldehyde (IV). The first NH, 65 intermediate product (IV) is heated gentlywvith a hydroxylamme affording the corresponding oxime: 4,6-d1- R l-kN /-R2 halo-S-pyrimidinecarboxaldehyde oxime (V). The second intermediate product (V) is dehydrated to a 4,6-dichloro- R S-pyrimidinecarbonitn'le (VI) by heating with a dehy- O where R is hydrogen or lower alkyl; R is cyano, carbox- 7 drating agent, such as thionyl chloride, for about 2 to amido or lower alkoxycarbonyl; R is hydrogen or lower 6 hours, preferably about 4 hours at reflux temperature. The third intermediate product is subjected to stepwise amination of the two halo groups. First the 4-halo group is replaced by stirring with an alcohol solution of ammonia at room temperature for about /2 to 1 /2 hours, preferably 1 hour, affording a 6-amino-4-halo-5- pyrimidinecarbonitrile (VII).

The 6-halo group may be replaced by a substituted methylamine by mixing the third intermediate product (VII) with substituted methylamine and heating at a temperature of about 70 to 90 C. for about 1 to 3 hours, preferably at the reflux temperature for about 2 /2 hours, thus affording a 6-amino-4-substituted methylamino-S-pyrimidinecarbonitrile (VIII). The fourth intermediate product (VIII) is cyclized by a Dieckmann type condensation to afford the product 4,5-diamino-6-substituted-7I -pyrrolo [2,3-a'] pyrimidine (I).

Where the starting material contains an acetamido substituted methylamine in the 6-position, the end product is a 4,5-diamino-7g-pyrrolo[2,3-d]pyrimidine-6-carboxamide. Where the starting material contains a cyanomethylamino group in the 6-position, the end product is a 4,5 diamino-7g-pyrrolo[2,3-d]pyrimidine-6-carbonitrile.

When the reaction is completed the product (I) may be separated by standard recovery methods. For instance, the reaction mixture may be chilled in ice and the resulting precipitate collected on a filter and then recrystallized from absolute alkanol.

By a similar process 2-lower alkylthio derivatives of the compounds of Formula I may be prepared by the following reaction scheme, where R and R are as described above, and R is lower alkyl.

(i 11 ITTHZ amination cyclizationl ITIHz (XII) The 6-amino 4 halo 2 (lower)alkylthio-5- pyrimidinecarbonitrile starting materials may be prepared as described in patent Serial No. 874,056 application entitled "S-Amino-2,4-Disubstituted Thieno[2,3-d]Pyrimidine-6-Carboxylic Acid Derivatives filed on the same date as the present application by D. H. Kim and A. A. Santilli.

The compounds may be prepared by mixing a 6-amino- 4-halo-2-(lower)alkylthio-S-pyrimidinecarbonitrile with a substituted methylamine solution and heating at a temperature of about 60 to 80 C. for about A to 3 hours, preferably at the reflux temperature for about one hour, thus affording a 6-amino-4-methylarnino-2(lower)alkylthio-S-pyrimidinecarbonitrile (XI). The latter intermediate product is cyclized by a Dieckmann type condensation to the 4,5-diamino-2-(lower)alkylthio-7E-pyrrolo[2,3-d] pyrimidines (XII).

Where the starting material co ta ns an acetamido sub- 4 stituted methylamino in the 6-position, the end product is a 4,5 diamino-2-(lower)alkylthio-7E-pyrrolo[2,3-d] pyrimidine-6-carboxamide. Where the starting material contains a cyanomethylamino group in the 6-position, the end product is a 4,5-diamino-2-(lower)alkylthio-7g-pyrrolo[2,3-a]pyrimidine-6-carbonitrile.

When the reaction is complete the product (XII) may be separated by standard recovery methods.

The 5-21l11lI10-4,6-diSL1bStitLlt6d-7E-PYITO1O [2,3-d] pyrimidines and 4,5-diamino-2-(lower)aIkylthio-G-substituted- 7fl-pyrrolo[2,3-d1pyrimidines of the present invention have utility in experimental and comparative pharmacology as central nervous system depressants. They produce a calming effect in the host at a dosage of 12.7 to 400 milligrams per kilogram of host body weight (MPK). All of the compounds are non-lethal in the dose range up to the maximum tested dose, 400 MPK, except 4,5- diamino-7-methyl 2 methylthio-7g-pyrrolo[2,3-d]pyrimidine-6-carbonitrile which is an effective depressant at a dose of 12.7 m.p.k. and was found to be non-lethal in doses as large as 127 m.p.k.; and 4,6-dichloro-2- phenyl 5 pyrimidinecarboxaldehyde, oxime which was lethal at a dose of 12.7 m.p.k. The latter compound however, is a useful intermediate in the production of other compounds as described above, which are active as central nervous system depressants.

In the pharmacological evaluation of the biological activity of the compounds of this invention, the in vivo effects are tested as follows. The compound is administered orally or intraperitoneall to three mice (14 to 24 grams) at each of the following doses: 400, 127, 40 and 12.7 m.p.k. The animals are watched for a minimum of two hours during which time signs of general stimulation, (i.e., increased spontaneous motor activity, hyperactivity on tactile stimulation, twitching), general depression (i.e., decreased spontaneous motor activity, decreased respiration), autonomic activity (i.e., miosis, mydriasis, diarrhea) are noted.

When the compounds of this invention are employed as described above, they may be administered alone or in combination with pharmacologically acceptable carriers,

the proportion of which is determined by the solubility and chemical nature of the compound, chosen route of administration and standard pharmacological practice. For example, they may be administered orally in the form of tablets or capsules containing such excipients as starch, milk, sugar, certain types of clay and so forth. They may be administered sublingually in the form of troches or lozenges in which the active ingredient is mixed with sugar and corn syrups; and then dehydrated suificiently to make it suitable for pressing into a solid form. They may be administered orally in the form of solutions which may contain coloring and flavoring agents or they may be injected parenterally, that is intra-muscularly, intravenously or subcutaneously. For parenteral administration they may be used in the form of a sterile solution containing other solutes, for example, enough saline or glucose to make the solution isotonic.

The dosage of the present therapeutic agents will vary with the form of administration and the particular compound chosen. Furthermore, it will vary with the particular subject under treatment. Generally, treatment is initiated with small dosages substantially less than the optimum dose of the compound. Therafter, the dosage is increased by small increments until the optimum effect under the circumstances is reached. It will generally be found that when the composition is administered orally, larger quantities of the active agent will be required to produce the same effect as a smaller quantity given parenterally. In general, the compounds of this invention are most desirably administered at a concentration level that will generally afford effective results without causing any harmful or deleterious side effects.

In order more clearly to disclose the nature of the present invention, specific examples of the practice of the invention are hereinafter given. It should be understood,-

however, that this is done solely by way of example and is intended neither to delineate the scope of the invention nor limit the ambit of the appended claims.

In theh examples all the temperatures are given in degrees centigrade and the following abbreviations are used: ml. for milliliters, hr." for hours, g. for grams, min. for minutes, and 25 for the phenyl group C H EXAMPLE I The following illustrates the preparation of 4,6-dichloro-2-phenyl-5-pyrimidinecarboxaldehyde which is a compound of structure IV.

To 180 ml. of phosphorus oxychloride in an ice bath was added portionwise 35 ml. of dimethylformamide. After allowing the resulting solution to stand at room temperature for 1 hr., 25 g. of 4,6-dihydroxy-2-phenylpyrimidine was added slowly. The resulting solution was allowed to stand for 30 min. and then was heated for 5 hr. on a steam bath. The phosphorus oxychloride was removed under reduced pressure, and the residue was slowly poured over ice. The solid that separated was collected on a filter and washed with water. The crude product was recrystallized from ethanol and then from heptane giving a product having a melting point of 154- 156.5.

The molecular formula C H CI N O was assumed for the product, and based on that formula it was calculated that the elemental analysis by weight would be 52.50 percent carbon, 2.39 percent hydrogen, 11.07 percent nitrogen and 28.02 percent chlorine. The assumed formula was determined to be accurate when it was found by analysis that the product actually contained 52.28 percent carbon, 2.41 percent hydrogen, 10.99 percent nitrogen and 27.77 percent chlorine. This ma be expressed:

Analysis.-Calcd. for C H CI N O (percent): C, 52.50; H, 2.39; N, 11.07; Cl, 28.02. Found (percent): C, 52.28; H, 2.41; N, 10.99; Cl, 27.77.

The product was evalulated in the foregoing pharmacological procedure and was found to decrease motor activity and respiration at a dose of 40 MPK administered parenterally Following the procedure of Example I but substituting appropriate starting materials, compounds having the following substituents may be obtained:

| TCHO 6 EXAMPLE 11 The following illustrates the preparation of 4,6-dichloro-2-phenyl-5-pyrimidinecarboxaldehyde, oxime which is a compound of structure V.

To a hot solution of 3.2 g. of hydroxylamine hydrochloride in 55 ml. aqueous acetic acid (50 ml. of glacial acetic acid, 5 ml. of Water) was added 10.0 g. of 4,6- dichloro-2-phenyl-S-pyrimidinecarboxaldehyde. The reaction solution Was heated gently for several minutes. Water was added until precipitation began. Chilling in ice afforded a solid, which was collected on a filter and washed several times with water. Recrystallization from ethanol atforded 2.2 g. of product having a melting point of 175-177.

Analysis.-Ca1cd. for CuHqClgNgO (percent): C, 49.28; H, 2.63; CI, 26.45; N, 15.67. Found (percent): C, 49.09; H, 2.67; Cl, 26.16; -N, 15.62.

The product was evaluated in the foregoing pharmacological procedure and was found to decrease motor activity and respiration at a dose of 40 m.p.k. administered parenterally.

Following the procedure of Example II but substituting appropriate starting materials, compounds having the following substituents may be obtained:

()1 N J CH=NOH 4- R KN C1 Example: R

JI II1 p-Cl II-2 p-Brq5- Ill-3 p-I II-4 p-F- II-S o-Cl- H-6 m-Cl lI-7 p-Br- II-8 4-CH II-9 3-C H H-10 3-C H II-ll 3-C H ]Il2 -h 3-CH O II-13 4-C H O- III-14 d 4'C3H10'- II-15 4-C H O 1I-16 3-CH II-17 4-C H 4-C3Hq' II-l9 4-C H EXAMPLE III The following illustrates the preparation of 4,6-dichloro- 2-phenyl-5-pyrimidinecarbonitrile which is a compound of structure V1.

IF k A solution of 3,7 g. of 4,6-dichloro-2-phenyl-5pyrimidinecarboxaldehyde, oxime and ml. of thionyl chloride was refluxed for 4 hr. The thionyl chloride was then removed under reduced pressure. The residue (2.9 g.) was recrystallized twice from ethyl acetate with charcoal treatment to give a pure compound having a melting point of 220.5-224.

Analysis.CalCd. for C H Cl N (percent): C, 52.83; H, 2.02; Cl, 28.35; N, 16.80. Found (percent): C, 52.81; H, 2.21; CI, 28.03; N, 1681.

The product was evaluated in the foregoing pharmacological procedure and was found to decrease motor activity and decrease respiration at a dose of 127 m.p.k. administered parenterally.

Following the procedure of Example III but substituting appropriate starting materials, compounds having the following substituents may be obtained:

l-CN 4 R KN Cl Example: R

III III-1 p-Cl-- III-2 p-Br III-3 p-I-- III-4 p-F III-5 o-Cl III-6 m-Cl III-7 p-Br 1114s 4-CH III-9 3-C H 3-C3H7 III-11 3-C H III-12 3-C-H O III-13 4-C H O III-14 4'C3H70 III-15 4-C H O III-16 3-CH III-17 4-C H III-18 4-C H III-19 4-C H EXAMPLE IV The following illustrates the preparation of 4-amino-6- chloro-2-phenyl-5-pyrimidinecarbonitrile which is a compound of structure VII.

Two and eight-tenths grams of 4,6-dichloro-2-phenyl- S-pyrimidinecarbonitrile was added to 50 ml. of ethanol saturated with ammonia, and the resulting mixture was stirred at room temperature for 1 hr. The precipitate which resulted was collected on a filter, and washed with water to give 2.3 g. of product having a melting point of 237-241". Recrystallization from absolute ethanol improved the melting point to 238240.

Analysis.Calcd. for C H N Cl (percent): C, 57.28; H, 3.06; N, 24.29; Cl, 15.37. Found (percent): C, 57.06; H, 3.07; N, 24.18; Cl, 15.04.

The product was evaluated in the foregoing pharmacological procedure and found to decrease motor activity and decrease respiration at a dose of 400 m.p.k. administered parenterally.

Following the procedure of Example IV but substituting appropriate starting materials, compounds having the following substituents may be obtained:

EXAMPLE V The following illustrates the preparation of 6-chloro-4- methylamino-Z-phenyL5-pyrimidinecarbonitrile which is a compound of structure VII.

IIIHCHa To a solution of 0.75 g. of methylamine in ml. of cold ethanol, was added 2.5 g. of 4,6-dichloro-2-phenyl-5- pyrimidinecarbonitrile. After stirring the mixture for 3 min. at 0, the solid was collected on a filter and recrystallized from benzene giving 1.2 g. of product having a melting point of 225428".

Analysis.Calcd. for C H ClN (percent): C, 58.90; H, 3.71; CI, 14.49; N, 22.90. Found (percent): C, 58.96; H, 3.83; CI, 14.23; N, 22.89.

The product was evaluated in the foregoing pharmacological procedure and found to decrease motor activity at a dose of 12.7 m.p.k. administered parenterally.

EXAMPLE VI The following illustrates the preparation of 4-chloro-6- ethylamino-2-pheny1-S-pyrimidinecarbonitrile which is a compound of structure VII.

an analytical sample having a melting point of 192 194.5.

EXAMPLE VII The following illustrates the preparation of 6-amino- 4 [(cyanomethyl)methylamino]-2-phenyl-5-pyrimidinecarbonitrile which is a compound of structure VIII.

IVE

A mixture of methylaminoacetonitrile hydrochloride (10.6 g.), and sodium bicarbonate (10 g.) in 70 ml. of absolute ethanol was heated with stirring under reflux for hr. To the refluxing mixture was added 5.6 g. of 4 amino-6-chloro-2-phenyl pyrimidinecarbonitrile. Refluxing was continued for an additional 2.5 hr. After cooling the reaction mixture to room temperature, the inorganic salt was removed by filtration, and the filtrate was concentrated under reduced pressure. Chilling of the concentrated solution caused separation of crystals which were collected on a tfilter and washed with water several times. Recrystallization of the crystals from absolute ethanol afforded 2.9 g. of product having a melting point of 202205.

Analysis.-Calcd. for C I-I N (percent): C, 63.62; H, 4.58; N, 31.80. Found (percent): C, 63.47; H, 4.54; N, 31.61.

The product was analysed in the foregoing pharmacological procedure and was found to decrease motor activity at a dose of 127 m.p.k. administered parenterally.

Following the procedure of Example VII but substituting appropriate starting materials, compounds having the following substituents may be obtained:

EXAMPLE VIII The following illustrates the preparation of 2[ (S-cyano- 6 methylamino 2 phenyl-4-pyrimidinyl)amino] acetamide which is a compound of structure VIII.

ITIHCH To a mixture of 15.4 g. of glycinamide hydrochloride, 11.2 g. of sodium bicarbonate and ml. of percent ethanol which had been refluxed for 45 min. was added 7.2 g. of 4-chloro-6-methylamino-2-phenyl-5- pyrimidinecarbonitrile and the resulting mixture was refluxed for 2 hr. After being chilled in ice, the mixture was filtered, and the collected material was washed with water and then with hot benzene. Recrystallizations from dimethylformamide-water gave the product having a melting point of 267.5270.

Analysis.Calcd. for C H N O (percent): C, 59.56; H, 5.00; N, 29.77. Found (percent): C, 59.85; H, 4.95; N, 29.54.

The product was evaluated in the foregoing pharmacological procedure and found to decrease motor activity at a dose of 127 m.p.k. administered parenterally.

EXAMPLE IX The following illustrates the preparation of 2-[(5-cyano- 6 ethylamino 2 phenyl-4-pyrimidylamino)acetamide which is a compound of structure VIII.

-NHCH C ONH ITIHCH2CH3 To a mixture of 10.0 g. of glycinamide hydrochloride, 7.55 g. of sodium bicarbonate and 200 ml. of 95 percent ethanol which had been refluxed for hr. was

added 6.1 g. of 4 chloro 6 ethylamino-Z-phenyl-S- pyrimidinecarbonitrile, and the resultant mixture was refluxed for 6 hr. After being chilled in ice, the compound was collected on a filter and Washed several times with water and then with ether giving 5.3 g. Recrystallization from dimethylformamidc-water gave a product having a melting point of 258261.

Analysis.--Calcd. for C H N O (percent): C, 60.79; H, 5.44; N, 28.36. Found (percent): C, 61.12; H, 5.57; N, 28.38.

The product was evaluated in the foregoing pharmacological procedure and found to decrease motor activity at a dose of 400 m.p.k. administered orally.

Following the procedure of Example IX but substituting appropriate starting materials, compounds having the following substituents may be obtained:

The following illustrates the preparation of 4,5-diaminobonitrile which is a compound of structure I.

IIII-I;

To a solution containing 0.18 g. of sodium in ml. of absolute ethanol was added 2.0 g. of 6-arnino-4-[(cyanomethyl)methylamino] 2-phenyl-5-pyrimidinecarbonitrile. The mixture was refluxed for 1.5 hr., chilled in ice and the resulting precipitate was collected on a filter to give 0.5 g. of product. The product was purified by recrystallizing from absolute ethanol and decomposed at 212-214.

Analysis.Calcd. for C H N percent): C, 63.62; H, 4.58; N, 31.80. Found (percent): C, 63.91; H, 4.54; N, 31.63.

The product was evaluated in the foregoing pharmacological procedure and found to decrease motor activity at a dose of 127 m.p.k. administered parenterally.

I 2 Following the procedure of Example X but substituting appropriate starting materials, compounds having the following substituents may be obtained:

The following illustrates the preparation of 5-amino-4- methylamino 2 phenyl-7g-pyrrolo] 2,3-d]pyrimidine-6- carboxamide which is a compound of structure I.

NHCH;

' NH, wk HCONH,

EXAMPLE XII The following illustrates the preparation of 5-amino-4- ethylamino 2-phenyl-7g-pyrrolo[2,3-d]pyrimidine-6-carboxamide which is a compound of structure I.

NHOHzCHa Win12 -L o ONHe To a sodium ethoxide solution (0.26 g. sodium, 50 ml. ethanol) was added 3.3 g. of 2-(5-cyano-6-ethylamino-2- phenyl -4-pyrimidylamino)acetamide, and the resulting mixture was refluxed for 40 min. After being chilled in ice a solid separated and was collected on a filter, washed with water and then ether. The product (2.5 g.) was recrystallized from dimethylformamide and had a melting point higher than 360.

Analysis.Calcd. for C H N O (percent): C, 60.79; H, 5.44; N, 28.36. Found: (percent) C, 60.79; H, 5.45; N, 28.09.

The following illustrates the preparation of 6-amino-4- cyanomethyl)methy1amino] 2 methylthio 5 pyrimidinecarbonitrile which is a compound of structure XI.

l '-oN oms- J-NCHQON A mixture of methylaminoacetonitrile hydrochloride (10.6 g.) and sodium bicarbonate g.) in 70' ml. of absolute ethanol was heated with stirring under reflux for 45 min. To the refluxing mixture was added 5.7 g. of 6- amino 4 chloro 2 methylthio 5 pyrimidinecarbonitrile. Refluxing was continued for an additional 2.5 hr. After cooling the reaction mixture to room temperature, the inorganic salt was removed by filtration, and the filtrate was concentrated under reduced pressure. Chilling of the concentrated solution caused separation of crystals which were collected on a filter and washed with water several times. Recrystallization of the crystals from absolute ethanol afforded 3.1 g. of product having a melting point of 205-207".

Analysis.Calcd. for C H N S (percent): C, 46.15; H, 4.30; N, 35.88; S, 13.66. Found (percent): C, 46.32; H, 4.09; N, 35.63; S, 13.94.

14 Following the procedure of Example XIII but substituting appropriate starting materials, compounds having the following substituents may be obtained;

H CH3 CH3 CH3 C2 5 C2 5 C3117 H C Hg CH3 H C211 CH3 CaH7 C211 C411 C3 1 C2135 C H9 H H CH CH3 H C2115 C4 9 C311 CH3 C 119 CH3 H H H CH3 CH3 C-lHg C2H C2115 C4 9 CH3 EXAMPLE XIV The following illustrates the preparation of 2-['(6- amino 5 cyano 2 methylthio 4 pyrimidyDamino] acetamide which is a compound of structure XI.

TCN ems-L NHomooNH,

To a mixture of 11 g. of glycinamide hydrochloride, 8.4 g. of sodium bicarbonate, and 70 m1. of percent ethanol which had been refluxed for 45 min. was added 5.9 g. of 4-amino-6-chloro-2-methylthio5-pyrimidinecarbonitrile and the resulting mixture was refluxed for 2 /2 hr. After being chilled in ice, the mixture was filtered, and the collected material was washed with water and then with hot benzene. The crude product was recrystallized from dimethylformamide giving a product which decomposed at 279-281.

Analysis.-Calcd. for C H N OS (percent): C, 40.33; H, 4.23; N, 35.28; S, 13.43. Found (percent): C, 40.30; H, 4.09; N, 34.82; S, 13.10.

The product was evaluated in the foregoing pharmacological procedure and found to decrease motor activity and respiration at a dose of 400 m.p.k. administered orally.

Following the procedure of Example XIV but substituting appropriate starting materials, compounds having the following substituents may be obtained:

The following illustrates the preparation of 4,5-diamino- 7 methyl 2 methylthio 7H pyrrlo[2,3 dJpyrimidine-tS-carbonitrile which is a compound of structure XII.

To a solution containing 0.2 g. of sodium in 30 ml. of absolute ethanol was added 2.3 g. of 6-amino-4-[(cyanomethyDmethylamino] 2 methylthio 5 pyrimidinecarbonitrile. The resulting mixture was refluxed for 1.5 hr. After cooling the reaction mixture the resulting precipitate was collected on a filter. The product amounted to 1.8 g. and decomposed at 238-240. Recrystallization from absolute ethanol raised the decomposition point to 240242.

Analysis.Cacld. for C H N s (percent): C, 46.15; H, 4.30; N, 35.88. Found (percent): C, 46.02; H, 4.09; N, 35.73.

The product was evaluated in the foregoing pharmacological procedure and found to decrease motor activity and respjrg iwl BI $1 dose of 12.7 m.p.k. administered orally.

16 Following the procedure of Example XV but substituting appropriate starting materials, compounds having the following substituents may be obtained:

The following illustrates the preparation of 4,5- diamino 2 methylthio -7 F I pyrrolo[2,3 d]pyrimidine-6-carboxamide which is a compound of structure XII.

To a sodium ethoxide solution (0.9 g. sodium, ml. ethanol) was added approximately 9.5 g. of 2-[(6-amino 5 cyano 2 methylthio 4 pyrimidinyl)amino]acetamide, and the resulting mixture was refluxed for 1 /2 hr. After being chilled in ice, the reaction product was collected on a filter and washed with a small amount of ethanol and then with Water. Recrystallization from dimethylformamide gave 1.4 g. of product having a melting point higher than 360.

Analysis.Calcd. for C H N OS (percent): C, 40.33; H, 4.23; N, 35.28; S, 13.43. Found (percent): C, 40.05; H, 4.16; N, 34.94; S, 13.57.

The product was evaluated in the foregoing pharmacological procedure and found to decrease motor activity and respiration at a dose of 127 m.p.k. administered parenterally.

17 Following the procedure of Example XVI but substituting appropriate starting materials, compounds having the following substituents may be obtained:

Whas is claimed is: 1. A compound selected from those having the formula:

ITIHRI NHz where R is hydrogen or lower alkyl; R is cyano, carboxamido or lower alkoxycarbonyl; R is hydrogen or lower alkyl; R is lower alkyl, phenyl, halophenyl, lower alkylphenyl, lower alkoxypheny1 or lower alkylthio.

2. A compound as defined in claim 1 which is: 4,5- diamino 7 methyl 2 phenyl 7g pyrrolo[2,3-d] pyrimidine-6-carbonitrile.

3. A compound as defined in claim 1 which is: 5- amino 4 methylamino 2 phenyl 7g pyrrolo [2,3- d pyrimidine-6-carboxamide.

4. A compound as defined in claim 1 which is: 5- amino 4 ethylamino 2 phenyl 7E pyrrolo[2,3- d]pyrimidine-6-carboxamide.

5. A compound as defined in claim 1 which is: 4,5- diamino 7 methyl 2 methylthio 7E pyrrolo[2,3- d]pyrimidine-G-carbonitrile.

6. A compound as defined in claim 1 which is: 4,5- diamino 2 methylthio 7g pyrrolo[2,3 dJpyrimidine-6-carboxamide.

References Cited UNITED STATES PATENTS 6/1962 Hitchings et al. 260256.4 F 1/1967 Partyka 260-2564 F US. Cl. X.R.

260-25l R, 256.4 F, 256 N; 424-251 Dated December 28 l9 7 l Patent No. qjq oLua Irwent fls) Dong H. Kim and Arthur A; Santilli It is certified that error appears in the above-identified patent and that said Letters Patent are hereby corrected as shown below:

At column 5, lines 50-55 in the formula Cl is omitted. w

The formula should be as follows:

At column 1 lines l t-l9 in theformula. CH shouldread CN. The formula should be as follows:

CN g CH CN 3 R L J Signed and sealed this 20th day of June 1972.

(SEAL) Attest:

EDWARD M.FLETCHER,JR. ROBERT GOTTSCHALK Attesting Officer Commissioner of Patents 

